This is a Briumvi news story, published by Investor's Business Daily, that relates primarily to TG Therapeutics news.
For more Briumvi news, you can click here:
more Briumvi newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
TG Therapeutics stock. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest multiple sclerosis drug news, multiple sclerosis news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
TG TherapeuticsInvestor's Business Daily
•
79% Informative
TG Therapeutics stock jumped more than 2% to 25.70 in early trading Wednesday .
The biotech company said 92% of patients who took its multiple sclerosis drug, Briumvi , didn't progress to disability after five years .
The annualized relapse rate over the course of five years was 0.02 , the equivalent to one relapse occurring in 50 years .
VR Score
82
Informative language
87
Neutral language
44
Article tone
formal
Language
English
Language complexity
47
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
4
Source diversity
2
Affiliate links
no affiliate links